© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 8, 572-573,
April 18, 2001
© 2001 Oxford University Press
EDITORIAL |
Intravesical Therapy for Bladder Cancer: Empiricism at the Helm
Correspondence to: James E. Montie, M.D., Department of Urology, University of Michigan, Ann Arbor, MI 481090330.
For more than 40 years, most patients with superficial bladder cancer have received one or more courses of intravesical chemotherapy or immunotherapy treatments during the course of their disease. Despite widespread use, reliable data to confirm the benefit of such treatment were generally lacking until the last 1015 years. Kilbridge and Kantoff (1), in a 1994 editorial, noted several problems with the many intravesical treatment publications: underpowered sample size, poor endpoints, poorly controlled or uncontrolled studies, and the grouping of primary tumor stages Ta, Tis, and T1 together and grades IIII together. A recent comprehensive review of the literature by the American Urological Association Bladder Cancer Clinical Guidelines Panel (2) found that only
REFERENCES